Skip to Content

Alnylam Pharmaceuticals Inc ALNY

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Narrow-Moat Alnylam Misses Q3 Revenue Estimates and Founding CEO Retires; Maintaining $158 FVE

Rachel Elfman Equity Analyst

Analyst Note

| Rachel Elfman |

Investors reacted negatively as Alnylam’s third-quarter results missed FactSet consensus estimates. During the quarter, Alnylam lost $1.72 per share, lower than FactSet consensus of a $1.59 loss per share. Nevertheless, Alnylam’s loss narrowed from negative $2.18 in the prior-year period. While sales grew 49% year over year to nearly $188 million, this was also behind FactSet estimates ($217 million). Additionally, management announced that its founding CEO, Dr. John Maraganore, will retire at the end of this year and transition CEO leadership to Alnylam’s current president and COO, Dr. Yvonne Greenstreet.

Read Full Analysis

Company Profile

Business Description

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has four drugs on the market: Onpattro for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. The firm also has 12 clinical programs across the following therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Additionally, up-front fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

675 West Kendall Street, Henri A. Termeer Square
Cambridge, MA, 02142
T +1 617 551-8200
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Sep 30, 2021
Fiscal Year End Dec 31, 2021
Stock Type Speculative Growth
Employees 1,453